The Medicines Company Presents Seven Hospital Data Analyses at Leading Health Economics and Outcomes Research Conferences

  The Medicines Company Presents Seven Hospital Data Analyses at Leading
  Health Economics and Outcomes Research Conferences

Business Wire

MONTREAL & BALTIMORE -- June 4, 2014

The Medicines Company (NASDAQ:MDCO) today announced that seven abstract poster
presentations are being delivered by the Company and its research
collaborators at this week’s International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) 19th Annual International Meeting in Montreal,
Canada, and at the American Heart Association Quality of Care and Outcome
Research (AHA QCOR) Scientific Sessions 2014 in Baltimore, MD. The abstracts
involve analyses within all three areas of hospital focus for The Medicines
Company: serious infectious disease care, acute cardiovascular care, and
surgery and perioperative care.

Stephanie Plent, MD, Executive Vice President and Chief Value Officer for The
Medicines Company stated, “The analyses we are presenting this week are
planned to provide a basis for our hospital customers to measure the impact of
introducing new solutions to their practice. This in turn serves a key part of
MDCO’s purpose, which is to contribute to the economics of healthcare."

SERIOUS INFECTIOUS DISEASE CARE

Three ISPOR posters in the serious infectious disease care area review involve
analysis of the Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
hospital market:

Severity and Costs of ABSSSI by Treatment Setting: An Application of the Eron
Classification to a Real-world Database

MDCO health economic researchers applied an algorithm for treatment of ABSSSI
known as Eron/CREST to real-world cost data from US hospitals from the Premier
hospital database (which contains one in every six discharges from US
hospitals). The Eron classification algorithm includes recommendations about
whether to hospitalize a patient or treat in an outpatient setting on the
basis of disease severity and comorbidities and – if hospitalized – when to
discharge the patient. It classifies patients from ABSSSI Class I (least
severe) to ABSSSI Class IV (life threatening). The analysis showed that
substantial proportions of patients in Class II (57.85%) and III (22.65%) were
not hospitalized, possibly reflecting a trend toward treatment of moderate
ABSSSI patients in the ambulatory setting.

Utilization, Costs and Reimbursement of Inpatient and Ambulatory Treatment of
ABSSSI Among the Medicare Fee-for-service Population; and Utilization, Costs
and Reimbursement of Inpatient Treatment of ABSSSI Among the Medicare
Fee-for-service Population

Two additional ISPOR poster abstracts examined utilization, costs and
reimbursement of inpatient and ambulatory treatment of ABSSSI among the
Medicare fee-for service populations, with costs derived from the Premier
hospital database. Data presented in the posters show a median length of stay
of three to four days for ABSSSI patients. Since seven to ten days of IV
reference therapy vancomycin is required, an average three to seven days of
antibiotic treatment is left for outpatient therapy. Despite discharging the
patients before the end of therapy, one analysis showed 52% of admissions for
the most common ABSSSI diagnosis were projected to result in financial losses
to the hospital; net reimbursement was positive for hospitals when the patient
length of stay was less than three days, but negative when more than three
days.

ACUTE CARDIOVASCULAR CARE

ISPOR: Estimating the Impact of Combining Cangrelor and Bivalirudin to a US
Hospital Performing PCI Procedures

This poster abstract described decision analysis modelling to cost data from
the Premier hospital database. The decision analytic model, based on current
PCI clinical practice, was developed to estimate the impact of using heparin +
provisional glycoprotein IIb/IIIa inhibitor (GPI) + clopidogrel (base case)
vs. bivalirudin + cangrelor + bailout GPI (scenario case).

AHA QCOR: CHAMPION PHOENIX Study Economic Results: Direct Hospitalization
Costs of Patients Receiving Clopidogrel or Cangrelor During Percutaneous
Coronary Intervention

Results of a pre-specified economic sub-study of the randomized Phase III
CHAMPION PHOENIX trial were presented at the AHA QCOR Scientific Sessions.
Actual hospital billing records from 1,117 patients enrolled in the US were
collected, certified, and analyzed using standard economic data quality
methods.

SURGERY AND PERIOPERATIVE CARE

ISPOR: Cardiovascular Surgery Pathway Microsimulation Framework to Study the
Health Economics of Clevidipine

This poster abstract described a decision-analytic microsimulation framework
that provides a basis for assessing economic properties of clevidipine use in
cardiac surgery.

ISPOR: An Analysis of Hospital Consumer Assessment of Healthcare Providers and
Services (HCAHPS) Scoring and the Impact of the Pain Management Dimension on
Hospital Performance

This study evaluated current Hospital Consumer Assessment of Healthcare
Providers and Systems (HCAHPS) pain measures across facilities, and analyzed
the potential benefit to overall HCAHPS scores by improving pain management in
an inpatient setting.

About The Medicines Company

The Medicines Company's purpose is to save lives, alleviate suffering, and
contribute to the economics of healthcare by focusing on 3,000 leading
acute/intensive care hospitals worldwide. Its vision is to be a leading
provider of solutions in three areas: acute cardiovascular care, surgery and
perioperative care, and serious infectious disease care. The company operates
in the Americas, Europe and the Middle East, and Asia Pacific regions with
global centers today in Parsippany, NJ, USA and Zurich, Switzerland.

About Angiomax® (bivalirudin) for Injection

In the United States, bivalirudin is marketed under the trade name Angiomax
and is indicated in patients undergoing PCI with provisional use of GPI and in
patients with, or at risk of, heparin-induced thrombocytopenia and thrombosis
syndrome (HIT/HITTS) undergoing PCI. In addition, Angiomax is also indicated
for use as an anticoagulant in patients with UA undergoing percutaneous
transluminal coronary angioplasty (PTCA). Angiomax is intended for use with
aspirin. Angiomax is not approved for use in patients with acute coronary
syndromes (ACS) not undergoing PCI or PTCA.

In clinical trials comparing Angiomax and heparin, the most common adverse
reaction for Angiomax was bleeding (28%). Other common adverse reactions were
headache, thrombocytopenia and fever. An unexplained fall in blood pressure or
hematocrit, or any unexplained symptom, should lead to serious consideration
of a hemorrhagic event and cessation of Angiomax administration. Angiomax
should be used with caution in patients with disease states associated with an
increased risk of bleeding.

In gamma brachytherapy, an increased risk of thrombus formation, including
fatal outcomes, has been associated with the use of Angiomax. Angiomax is
contraindicated in patients with active major bleeding or hypersensitivity to
Angiomax or its components.

Please see full prescribing information for Angiomax, available at
http://www.angiomax.com.

About Cangrelor

Cangrelor is an investigational agent not approved for commercial use in any
market. Cangrelor, an immediately bioavailable and quickly reversible
intravenous small molecule antiplatelet agent, is in development to prevent
platelet activation and aggregation that leads to thrombosis in the acute care
setting, including in patients undergoing PCI.

The cangrelor NDA filing was based on the results of a development program
which included the data from four randomized, double-blind clinical trials
conducted in 25,567 patients with coronary artery disease (CHAMPION PHOENIX,
CHAMPION PLATFORM, CHAMPION PCI, and BRIDGE). The PHOENIX study provided the
primary evidence of efficacy for the proposed PCI indication for cangrelor.

About Cleviprex® (clevidipine) Injectable Emulsion

Cleviprex® (clevidipine) is an intravenous dihydropyridine calcium channel
blocker indicated for the reduction of blood pressure when oral therapy is not
feasible or not desirable. In June 2011, the U.S. Food and Drug Administration
(FDA) approved the current formulation, which triples the maximum allowable
infusion time per vial, commonly referred to in hospitals as "hang time," to
12 hours compared to the original 4-hour hang time vial approved by the FDA in
2008.

Cleviprex is contraindicated in patients with allergies to soybeans, soy
products, eggs or egg products; defective lipid metabolism; and severe aortic
stenosis.

Cleviprex is intended for intravenous use. Use aseptic technique and discard
any unused product within 12 hours of stopper puncture. Hypotension and reflex
tachycardia are potential consequences of rapid upward titration of Cleviprex.
Dihydropyridine calcium channel blockers can produce negative inotropic
effects and exacerbate heart failure. Monitor heart failure patients
carefully.

Cleviprex gives no protection against the effects of abrupt beta-blocker
withdrawal.

Patients who receive prolonged Cleviprex infusions and are not transitioned to
other antihypertensive therapies should be monitored for the possibility of
rebound hypertension for at least 8 hours after the infusion is stopped.

Most common adverse reactions are ( > 2%) headache, nausea, and vomiting.

Forward-looking Statements

Statements contained in this press release about The Medicines Company that
are not purely historical, and all other statements that are not purely
historical, may be deemed to be forward-looking statements for purposes of the
safe harbor provisions under The Private Securities Litigation Reform Act of
1995. Without limiting the foregoing, the words "believes," "plans,"
"anticipates" and "expects" and similar expressions, including the Company's
preliminary revenue results, are intended to identify forward-looking
statements. These forward-looking statements involve known and unknown risks
and uncertainties that may cause the Company's actual results, levels of
activity, performance or achievements to be materially different from those
expressed or implied by these forward-looking statements. Important factors
that may cause or contribute to such differences include whether its
regulatory submissions will receive approvals from regulatory agencies on a
timely basis or at all, whether physicians, patients and other key decision
makers will accept clinical trial results, and such other factors as are set
forth in the risk factors detailed from time to time in the Company's periodic
reports and registration statements filed with the Securities and Exchange
Commission including, without limitation, the risk factors detailed in the
Company's Quarterly Report on Form 10-Q filed on May 12, 2014, which are
incorporated herein by reference. The Company specifically disclaims any
obligation to update these forward-looking statements.

Contact:

The Medicines Company
Neera Dahiya Ravindran, MD, +1-973-290-6044
Vice President, Investor Relations & Strategic Planning
neera.ravindran@themedco.com
 
Press spacebar to pause and continue. Press esc to stop.